This article was originally published in Start Up
Executive SummaryA great deal of occlusive disease cannot be treated with stents and conventional angioplasty balloons. Some 30% of lesions are complex and require special methods or tools because they're hard and calcified, because the lesions are ostial or located at bifurcations, because they're in vessels prone to elastic recoil, because disease is long and diffuse, or because they are otherwise unstentable. It is exactly this set of challenges that AngioScore has set out to address.
You may also be interested in...
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.